Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis
| العنوان: | Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis |
|---|---|
| المؤلفون: | Sara A AlMuhaini, Khalid M. Alkharfy, Bashayer Alotaibi, Hadeel Alkofide, Abdullah Almohaizeie |
| المصدر: | International Journal of Infectious Diseases, Vol 110, Iss, Pp 320-329 (2021) International Journal of Infectious Diseases |
| بيانات النشر: | Elsevier BV, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Microbiology (medical), medicine.medical_specialty, systemic corticosteroid therapy, coronavirus, MEDLINE, severe COVID-19, Infectious and parasitic diseases, RC109-216, Disease, Antibodies, Monoclonal, Humanized, Article, law.invention, tocilizumab, chemistry.chemical_compound, Tocilizumab, Randomized controlled trial, Adrenal Cortex Hormones, law, Internal medicine, medicine, Humans, SARS-CoV-2, business.industry, Mortality rate, COVID-19, General Medicine, Confidence interval, COVID-19 Drug Treatment, Infectious Diseases, chemistry, Meta-analysis, Relative risk, business |
| الوصف: | Background To date, there is no effective treatment for the new coronavirus disease (COVID-19). We aimed to systematically review the literature on the association between the combination of tocilizumab (TCZ) and systemic corticosteroid therapy (SCT) on outcomes of COVID-19 patients. Methods We searched MEDLINE, Cochrane Central, and preprints, for studies in which health outcomes were compared between adults with severe COVID-19 who received TCZ and SCT and those who received standard of care without TCZ. Record screening, data extraction, and risk of bias assessment were performed in duplicate. Random effect models were used when pooling crude numbers and adjusted effect estimates of study outcomes. Results Our search identified seventeen studies. The pooled crude mortality rate was lower in the combination arm (relative risk, RR=0.62, 95% confidence interval [CI]=0.42 – 0.91; I2=60%). The adjusted mortality rates were also lower in the combination arm (RR=0.58, 95% CI=0.42 – 0.81; I2=71%). The rate of superinfections did not differ between the two interventions. Conclusions The findings of this study show that combination of TCZ and SCT compared to SOC has lower mortality rates. There is an urgent need for well-designed randomized trials to assess the safety and efficacy of this combination in subjects with severe COVID-19. |
| تدمد: | 1201-9712 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c8354dd077bb3d166f7b50c99356d8fTest https://doi.org/10.1016/j.ijid.2021.07.021Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1c8354dd077bb3d166f7b50c99356d8f |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....1c8354dd077bb3d166f7b50c99356d8f 893 3 unknown 893.099975585938 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1c8354dd077bb3d166f7b50c99356d8f&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Sara+A+AlMuhaini%22">Sara A AlMuhaini</searchLink><br /><searchLink fieldCode="AR" term="%22Khalid+M%2E+Alkharfy%22">Khalid M. Alkharfy</searchLink><br /><searchLink fieldCode="AR" term="%22Bashayer+Alotaibi%22">Bashayer Alotaibi</searchLink><br /><searchLink fieldCode="AR" term="%22Hadeel+Alkofide%22">Hadeel Alkofide</searchLink><br /><searchLink fieldCode="AR" term="%22Abdullah+Almohaizeie%22">Abdullah Almohaizeie</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => International Journal of Infectious Diseases, Vol 110, Iss, Pp 320-329 (2021)<br />International Journal of Infectious Diseases ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Elsevier BV, 2021. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2021 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Microbiology+%28medical%29%22">Microbiology (medical)</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22systemic+corticosteroid+therapy%22">systemic corticosteroid therapy</searchLink><br /><searchLink fieldCode="DE" term="%22coronavirus%22">coronavirus</searchLink><br /><searchLink fieldCode="DE" term="%22MEDLINE%22">MEDLINE</searchLink><br /><searchLink fieldCode="DE" term="%22severe+COVID-19%22">severe COVID-19</searchLink><br /><searchLink fieldCode="DE" term="%22Infectious+and+parasitic+diseases%22">Infectious and parasitic diseases</searchLink><br /><searchLink fieldCode="DE" term="%22RC109-216%22">RC109-216</searchLink><br /><searchLink fieldCode="DE" term="%22Disease%22">Disease</searchLink><br /><searchLink fieldCode="DE" term="%22Antibodies%2C+Monoclonal%2C+Humanized%22">Antibodies, Monoclonal, Humanized</searchLink><br /><searchLink fieldCode="DE" term="%22Article%22">Article</searchLink><br /><searchLink fieldCode="DE" term="%22law%2Einvention%22">law.invention</searchLink><br /><searchLink fieldCode="DE" term="%22tocilizumab%22">tocilizumab</searchLink><br /><searchLink fieldCode="DE" term="%22chemistry%2Echemical%5Fcompound%22">chemistry.chemical_compound</searchLink><br /><searchLink fieldCode="DE" term="%22Tocilizumab%22">Tocilizumab</searchLink><br /><searchLink fieldCode="DE" term="%22Randomized+controlled+trial%22">Randomized controlled trial</searchLink><br /><searchLink fieldCode="DE" term="%22Adrenal+Cortex+Hormones%22">Adrenal Cortex Hormones</searchLink><br /><searchLink fieldCode="DE" term="%22law%22">law</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22SARS-CoV-2%22">SARS-CoV-2</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Mortality+rate%22">Mortality rate</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19%22">COVID-19</searchLink><br /><searchLink fieldCode="DE" term="%22General+Medicine%22">General Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Confidence+interval%22">Confidence interval</searchLink><br /><searchLink fieldCode="DE" term="%22COVID-19+Drug+Treatment%22">COVID-19 Drug Treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Infectious+Diseases%22">Infectious Diseases</searchLink><br /><searchLink fieldCode="DE" term="%22chemistry%22">chemistry</searchLink><br /><searchLink fieldCode="DE" term="%22Meta-analysis%22">Meta-analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Relative+risk%22">Relative risk</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background To date, there is no effective treatment for the new coronavirus disease (COVID-19). We aimed to systematically review the literature on the association between the combination of tocilizumab (TCZ) and systemic corticosteroid therapy (SCT) on outcomes of COVID-19 patients. Methods We searched MEDLINE, Cochrane Central, and preprints, for studies in which health outcomes were compared between adults with severe COVID-19 who received TCZ and SCT and those who received standard of care without TCZ. Record screening, data extraction, and risk of bias assessment were performed in duplicate. Random effect models were used when pooling crude numbers and adjusted effect estimates of study outcomes. Results Our search identified seventeen studies. The pooled crude mortality rate was lower in the combination arm (relative risk, RR=0.62, 95% confidence interval [CI]=0.42 – 0.91; I2=60%). The adjusted mortality rates were also lower in the combination arm (RR=0.58, 95% CI=0.42 – 0.81; I2=71%). The rate of superinfections did not differ between the two interventions. Conclusions The findings of this study show that combination of TCZ and SCT compared to SOC has lower mortality rates. There is an urgent need for well-designed randomized trials to assess the safety and efficacy of this combination in subjects with severe COVID-19. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1201-9712 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c8354dd077bb3d166f7b50c99356d8f" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c8354dd077bb3d166f7b50c99356d8f</link><br /><link linkTarget="URL" linkTerm="https://doi.org/10.1016/j.ijid.2021.07.021" linkWindow="_blank">https://doi.org/10.1016/j.ijid.2021.07.021</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....1c8354dd077bb3d166f7b50c99356d8f ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 10
[StartPage] => 320
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Adult
[Type] => general
)
[1] => Array
(
[SubjectFull] => Microbiology (medical)
[Type] => general
)
[2] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[3] => Array
(
[SubjectFull] => systemic corticosteroid therapy
[Type] => general
)
[4] => Array
(
[SubjectFull] => coronavirus
[Type] => general
)
[5] => Array
(
[SubjectFull] => MEDLINE
[Type] => general
)
[6] => Array
(
[SubjectFull] => severe COVID-19
[Type] => general
)
[7] => Array
(
[SubjectFull] => Infectious and parasitic diseases
[Type] => general
)
[8] => Array
(
[SubjectFull] => RC109-216
[Type] => general
)
[9] => Array
(
[SubjectFull] => Disease
[Type] => general
)
[10] => Array
(
[SubjectFull] => Antibodies, Monoclonal, Humanized
[Type] => general
)
[11] => Array
(
[SubjectFull] => Article
[Type] => general
)
[12] => Array
(
[SubjectFull] => law.invention
[Type] => general
)
[13] => Array
(
[SubjectFull] => tocilizumab
[Type] => general
)
[14] => Array
(
[SubjectFull] => chemistry.chemical_compound
[Type] => general
)
[15] => Array
(
[SubjectFull] => Tocilizumab
[Type] => general
)
[16] => Array
(
[SubjectFull] => Randomized controlled trial
[Type] => general
)
[17] => Array
(
[SubjectFull] => Adrenal Cortex Hormones
[Type] => general
)
[18] => Array
(
[SubjectFull] => law
[Type] => general
)
[19] => Array
(
[SubjectFull] => Internal medicine
[Type] => general
)
[20] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[21] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[22] => Array
(
[SubjectFull] => SARS-CoV-2
[Type] => general
)
[23] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[24] => Array
(
[SubjectFull] => Mortality rate
[Type] => general
)
[25] => Array
(
[SubjectFull] => COVID-19
[Type] => general
)
[26] => Array
(
[SubjectFull] => General Medicine
[Type] => general
)
[27] => Array
(
[SubjectFull] => Confidence interval
[Type] => general
)
[28] => Array
(
[SubjectFull] => COVID-19 Drug Treatment
[Type] => general
)
[29] => Array
(
[SubjectFull] => Infectious Diseases
[Type] => general
)
[30] => Array
(
[SubjectFull] => chemistry
[Type] => general
)
[31] => Array
(
[SubjectFull] => Meta-analysis
[Type] => general
)
[32] => Array
(
[SubjectFull] => Relative risk
[Type] => general
)
[33] => Array
(
[SubjectFull] => business
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sara A AlMuhaini
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Khalid M. Alkharfy
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bashayer Alotaibi
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hadeel Alkofide
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Abdullah Almohaizeie
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 09
[Type] => published
[Y] => 2021
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 12019712
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 110
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => International Journal of Infectious Diseases
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |